Pentixapharm Holding AG (ETR:PTP)

Pentixapharm Holding AG Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024
Period Ending	Mar 31, 2025	Dec 31, 2024
Operating Revenue	0.14	0.78
Other Revenue	-	0.62
Revenue	0.14	1.4
Cost of Revenue	4.93	3.74
Gross Profit	-4.8	-2.33
Selling, General & Admin	2.86	2.26
Other Operating Expenses	2.07	2.73
Operating Expenses	5.91	5.06
Operating Income	-10.7	-7.39
Interest Expense	-0.05	-0.1
Interest & Investment Income	0.58	0.57
Currency Exchange Gain (Loss)	0.01	0.01
EBT Excluding Unusual Items	-10.07	-6.91
Impairment of Goodwill	-0.78	-0.78
Gain (Loss) on Sale of Assets	6.7	6.7
Asset Writedown	-18.24	-18.24
Other Unusual Items	1.72	1.72
Pretax Income	-20.66	-17.5
Income Tax Expense	-3.81	-3.52
Net Income	-16.86	-13.98
Net Income to Common	-16.86	-13.98
Shares Outstanding (Basic)	25	25
Shares Outstanding (Diluted)	25	25
EPS (Basic)	-0.68	-0.56
EPS (Diluted)	-0.68	-0.57
Free Cash Flow	-10.17	-7.35
Free Cash Flow Per Share	-0.41	-0.30
Gross Margin	-	-166.38%
Operating Margin	-7811.68%	-527.20%
Profit Margin	-12303.65%	-996.43%
Free Cash Flow Margin	-7424.09%	-524.24%
EBITDA	-9.73	-7.33
D&A For EBITDA	0.97	0.07
EBIT	-10.7	-7.39

Source: S&P Global Market Intelligence. Standard template. Financial Sources.